Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1813 3
1814 2
1815 1
1851 1
1867 1
1928 1
1930 1
1935 1
1938 1
1943 1
1947 4
1948 5
1949 3
1950 7
1951 6
1952 4
1953 7
1954 3
1955 4
1956 6
1957 9
1958 8
1959 10
1960 13
1961 11
1962 9
1963 7
1964 8
1965 19
1966 12
1967 16
1968 11
1969 17
1970 18
1971 19
1972 12
1973 16
1974 16
1975 25
1976 23
1977 20
1978 26
1979 11
1980 22
1981 26
1982 16
1983 20
1984 20
1985 17
1986 19
1987 31
1988 24
1989 27
1990 46
1991 48
1992 55
1993 50
1994 34
1995 43
1996 33
1997 24
1998 25
1999 26
2000 33
2001 52
2002 34
2003 31
2004 46
2005 58
2006 69
2007 70
2008 56
2009 49
2010 65
2011 73
2012 65
2013 58
2014 70
2015 95
2016 68
2017 66
2018 79
2019 79
2020 99
2021 99
2022 75
2023 89
2024 86
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,505 results

Results by year

Filters applied: . Clear all
Page 1
MECP2-Related Disorders in Males.
Pascual-Alonso A, Martínez-Monseny AF, Xiol C, Armstrong J. Pascual-Alonso A, et al. Among authors: armstrong j. Int J Mol Sci. 2021 Sep 4;22(17):9610. doi: 10.3390/ijms22179610. Int J Mol Sci. 2021. PMID: 34502518 Free PMC article. Review.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Among authors: armstrong j. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA, Abbracchio MP, Abraham G, Agoulnik A, Alexander W, Al-Hosaini K, Bäck M, Baker JG, Barnes NM, Bathgate R, Beaulieu JM, Beck-Sickinger AG, Behrens M, Bernstein KE, Bettler B, Birdsall NJM, Blaho V, Boulay F, Bousquet C, Bräuner-Osborne H, Burnstock G, Caló G, Castaño JP, Catt KJ, Ceruti S, Chazot P, Chiang N, Chini B, Chun J, Cianciulli A, Civelli O, Clapp LH, Couture R, Cox HM, Csaba Z, Dahlgren C, Dent G, Douglas SD, Dournaud P, Eguchi S, Escher E, Filardo EJ, Fong T, Fumagalli M, Gainetdinov RR, Garelja ML, de Gasparo M, Gerard C, Gershengorn M, Gobeil F, Goodfriend TL, Goudet C, Grätz L, Gregory KJ, Gundlach AL, Hamann J, Hanson J, Hauger RL, Hay DL, Heinemann A, Herr D, Hollenberg MD, Holliday ND, Horiuchi M, Hoyer D, Hunyady L, Husain A, IJzerman AP, Inagami T, Jacobson KA, Jensen RT, Jockers R, Jonnalagadda D, Karnik S, Kaupmann K, Kemp J, Kennedy C, Kihara Y, Kitazawa T, Kozielewicz P, Kreienkamp HJ, Kukkonen JP, Langenhan T, Larhammar D, Leach K, Lecca D, Lee JD, Leeman SE, Leprince J, Li XX, Lolait SJ, Lupp A, Macrae R, Maguire J, … See abstract for full author list ➔ Alexander SPH, et al. Among authors: armstrong jf. Br J Pharmacol. 2023 Oct;180 Suppl 2:S23-S144. doi: 10.1111/bph.16177. Br J Pharmacol. 2023. PMID: 38123151 Free article.
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. Wagenlehner FM, et al. Among authors: armstrong j. Clin Infect Dis. 2016 Sep 15;63(6):754-762. doi: 10.1093/cid/ciw378. Epub 2016 Jun 16. Clin Infect Dis. 2016. PMID: 27313268 Free PMC article. Clinical Trial.
Ultrasound-Triggered Enzymatic Gelation.
Nele V, Schutt CE, Wojciechowski JP, Kit-Anan W, Doutch JJ, Armstrong JPK, Stevens MM. Nele V, et al. Among authors: armstrong jpk. Adv Mater. 2020 Feb;32(7):e1905914. doi: 10.1002/adma.201905914. Epub 2020 Jan 10. Adv Mater. 2020. PMID: 31922627 Free PMC article.
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. Mazuski JE, et al. Among authors: armstrong j. Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8. Clin Infect Dis. 2016. PMID: 26962078 Free PMC article. Clinical Trial.
Mitochondria-directed therapeutics.
Armstrong JS. Armstrong JS. Antioxid Redox Signal. 2008 Mar;10(3):575-8. doi: 10.1089/ars.2007.1929. Antioxid Redox Signal. 2008. PMID: 18092938
A blueprint for translational regenerative medicine.
Armstrong JPK, Keane TJ, Roques AC, Patrick PS, Mooney CM, Kuan WL, Pisupati V, Oreffo ROC, Stuckey DJ, Watt FM, Forbes SJ, Barker RA, Stevens MM. Armstrong JPK, et al. Sci Transl Med. 2020 Dec 2;12(572):eaaz2253. doi: 10.1126/scitranslmed.aaz2253. Sci Transl Med. 2020. PMID: 33268507 Free PMC article. Review.
2,505 results